anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a fibrosis-suppressing agent effective in suppressing the fibrosis of organs and useful for the treatment of fibrosis by using a gallic acid ester as an active component. CONSTITUTION:The objective agent contains a gallic acid ester of formula (R is 1-20C alkyl, 2-20C alkenyl, aryl, cycloalkyl, aralkyl, etc.) as an active component. The compound can be produced by a conventional process comprising the reaction of a gallic acid halide with an alcohol. The content of the active component in the agent is 0.1-500 mg per unit dose and the component is administered at a daily rate of 5-300 mg by oral administration or 0.1-50mg/kg by parenteral administration for adult. A gallic acid ester is effective in suppressing the formation of collagen fiber of a fiber-forming mutant cell (M- strain cell) originated from a rat liver cell at a low concentration. (+)- Catechin-3'-O-gallate and (+)-catechin-4'-O-gallate, etc., obtained from a wild grape are also preferable examples of the gallic acid ester.
Participants will receive cigarettes with the lowest nicotine dose (.03 mb nicotine yield). They will receive a targeted intervention workbook ("Count down: Preparing to Quit Smoking with Low-Nicotine Cigarettes") and will be provided with one-on-one counseling.
A nebulizer-filter device for delivering aerosolized medicament to a respiratory system of a patient is disclosed. The device comprises a filter (904), a first port, a second port (912) and a nebulizer (902). The replaceable filter (904) is held by coupling together opposite facing first (906) and second holding elements. The first port is formed in the first holding element (906) and the second port (912) is formed in the second holding element. The nebulizer (902) generates the aerosolized medicament and is detachably coupled to the first port. A patient respiratory interface is detachably coupled to the second port (912). The aerosolized medicament travels from the nebulizer (902) to the respiratory system of the patient during a patient inhalation phase, and residual aerosolized medicament passes through the filter (904) during a patient exhalation phase.
Hodgkin-lymphoma is a rare malignancy among children and adolescents (about 140 each year in Germany) which is highly curable. Beside this therapeutic success, a lot of therapy-related long-term problems arise (e.g. fertility disorders, thyroid diseases, secondary malignancies). While most of the studies focused on mental and physical impairments, little attention has been drawn to social dimensions of health. Due to the disease and the requirements of the therapy, participation of children with hodgkin-lymphoma can be impaired acutely or chronically. This can be of serious consequences, because participation in daily life is an important component of the development of children and adolescents. To determine the influence of social, personal and treatment-related factors on participation, all patients who were actual treated in the international therapy study EuroNet-PHL-C2 in all of Germany (N ≈ 700) and their parents will be interviewed. Statistical analyses will be done using descriptive and multivariate methods taking account of treatment-related issues (e.g. stage of disease, chemotherapy, radiotherapy, progression/relapse).
It has already been known for a long time that cancer is a genetic disorder and that the development of the illness is a very complex interaction between genetic and surrounding factors. Also the response on therapy and the development and seriousness of side effects is stipulated by this complicated collaboration of genetic and surrounding factors. Moreover it is not only the DNA that plays an important role but also the systems of control at protein level. At this moment a lot of questions remain to be answered because up till now the studies were of rather restricted statistic strength with frequently inconsistent dates and moreover retrospective. Major retrospective studies are necessary to distinguish the relationship between DNA/protein patterns and clinical relevant endpoints like prognosis and toxicity in which an as broad as possible patient group is being monitored. For this reason we want to take blood samples in MAASTRO clinic of all patients with lung cancer and to store it encrypted so that we can perform DNA and protein analyses in future and to correlate the results with survival and toxicity of the treatment.
The invention is directed to the field of gene therapy, i.e. gene delivery into target cells, tissue, organ and organism, and more particularly to gene delivery via viral vectors. The inventors showed that it is possible by chemical coupling to modulate the coupling of a ligand in the surface of the capsid of AAV, for example AAV2 and AAV3b. In particular, the present invention relates to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. Particularly, the inventors tested the chemical coupling of mannose ligand on AAV2 for subretinally injection to rats. The present invention further relates to a method for chemically coupling an Adeno-Associated Virus (AAV) vector particle with at least one ligand L and to a Recombinant Adeno-Associated Virus (rAAV) vector particle obtained by said method as well as a pharmaceutical composition comprising it and their corresponding medical use.
The present invention provides a fermented herbal medicinal composition having an antioxidant activity, and to a method for producing the same, wherein the fermented herbal medicinal composition includes fermented extracts of malt, red beans, and kelp as active ingredients. Since the fermented herbal medicinal composition contains no synthetic components and only contains natural components including malt, red beans, and kelp, the fermented herbal medicinal composition is not harmful to the human body. In particular, starch accounting for a large proportion of the natural components has a high molecular weight and has a low in vivo absorption rate, but when being fermented, the starch is decomposed and glucose is produced, so the in vivo absorption rate thereof is increased. Accordingly, bioavailability is improved, and thus an antioxidant activity is also improved. Moreover, compared to an extract obtained by extracting an herbal medicinal composition without a pretreatment, a fermented extract extracted after fermentation has a high yield, and the content of protein, carbohydrate, and phenol in the extract is also high. Even when each of malt, red beans, and kelp is used, an antioxidant activity is shown. However, when malt, red beans, and kelp are all included, a more excellent antioxidant activity is shown.
PURPOSE: To obtain an oil and fat from material(s) not occurring in nature, useful for surfactants, food additives, raw materials for fatty acids, etc., by culturing such bacterial as to be capable of accumulating oil and fat through assimilating chain hydrocarbons in a chain hydrocarbon-contg. medium. CONSTITUTION: Bacterium capable of accumulating an oil and fat through assimilating chain hydrocarbons, e.g. Mycobacterium sp. KO-201 strain (FERM P-14532), is cultured in a chain hydrocarbon-contg. medium and the resultant oil and fat accumulated in the microbes is taken out. Thereby, an oil and fat can also be obtained from material(s) other than raw materials derived from naturally-generating animals/plants, and a non-natural type oil and fat containing fatty acid residues having odd number of carbon atoms can also be produced.
During surgery, the line of intended bowel transection would be determined by the surgeon. Then the anesthesiologist will administer a bolus of 5mg ICG intravenously (2.5mg/ml, 2ml), followed by 10ml normal saline flush. The perfusion of colon will be assessed via fluorescence angiography. The actual bowel transection, after ICG fluorescence study, would be compared with the intended bowel transection site. The difference in terms of distance and either more proximal or distal is recorded. Then bowel anastomosis is completed in the usual manner.
PURPOSE: To obtain a cosmetic capable of sufficiently exhibiting a characteristic feature of natural water to the skin and giving excellent usability on it such as soft and moist feeling after use by adjusting pH of the natural water into a specific range within a specific period after collection. CONSTITUTION: This cosmetic is produced by compounding a natural water whose pH is adjusted into 2.5-4 or 8.7-11 within 7 days, preferably within 3 days after collection. The natural water is preferably collected from the foot of Mt. Fuji, Rokkou mountain in Hyogo prefecture, etc. Further, the compounding ratio of the natural water is preferably >=3wt.% for a cosmetic lotion and >=2wt.% for a solid cosmetic having a stick-shape, a pencil-shape, etc., such as a lipstick based on the total amount of the cosmetic. Concretely, the adjustment of pH is performed e.g. with hydrochloric acid or NaOH adding in an amount of 0.001wt.%.
BACKGROUND: The triglyceride-glucose (TyG) index is a risk marker for arterial stiffness; however, the extent to which the TyG index is associated with arterial stiffness via lipids and inflammation remains unknown. The first aim was to probe the relationship between the TyG index and arterial stiffness in two surveys. The second aim was to clarify whether lipids and inflammation mediate this relationship.
METHODS: The sample size of 13,726 U.S. individuals from the National Examination Survey (NHANES) and 3,964 Chinese individuals from the China Health and Retirement Longitudinal Study (CHARLS 2015) were enrolled. Weighted multivariate logistic and linear regression models, as well as restricted cubic spline (RCS) and mediation analyses, were utilized to estimate complex relationships between the TyG index, arterial stiffness, lipids (non-high-density lipoprotein cholesterol [non-HDL-C]) and inflammation (C-reactive protein [CRP]) biomarkers.
RESULTS: A total of 3,420 U.S. patients and 992 Chinese patients were diagnosed with increased arterial stiffness. Regression analyses demonstrated that higher quartiles of the TyG index were associated with a greater incidence of increased arterial stiffness (NHANES: OR = 2.610, 95% CI = 2.043-3.334, P < 0.001; CHARLS: OR = 1.579, 95% CI = 1.057-2.360, P < 0.001). Participants with a higher TyG index/higher CRP level or with a higher TyG index/higher non-HDL-C level had the highest incidence of increased arterial stiffness in the two surveys. The results were still consistent when the sensitivity analysis was implemented with stricter clinical cut-off values of non-HDL-C. Mediation analysis verified that lipids (mediated effect: β = 0.012, P < 0.001 in NHANES; β = 0.020, P < 0.001 in CHARLS) and inflammation (mediated effect: β = 0.003, P < 0.001 in NHANES; β = 0.006, P < 0.001 in CHARLS) partially mediated this relationship.
CONCLUSIONS: These results indicated a positive linear correlation between the TyG index, non-HDL-C level, CRP level and increased arterial stiffness in two surveys. Furthermore, lipids and inflammation could partly mediate the correlation of the TyG index with arterial stiffness in both surveys.
Multiple sclerosis (MS) is a neurodegenerative disease that affects the central nervous system (CNS) generating neuropathic pain and anxiety. Primary progressive MS (PPMS) is the most disabling clinical form, and the patients present an intense neurodegenerative process. In this context, the advanced oxidation protein products (AOPPs) are oxidized compounds and their accumulation in plasma has been related to clinical disability in MS patients. However, the involvement of AOPPs in neuropathic pain- and anxiety-like symptoms was not previously evaluated. To assess this, female mice C57BL/6J were used to induce progressive experimental autoimmune encephalomyelitis (PMS-EAE). Clinical score, weight, strength of plantar pressure, rotarod test, mechanical allodynia, and cold hypersensitivity were evaluated before induction (baseline) and on days 7th, 10th, and 14th post-immunization. We assessed nest building, open field, and elevated plus-maze tests 13 days post-immunization. Animals were killed at 14 days post-immunization; then, AOPPs levels, NADPH oxidase, and myeloperoxidase (MPO) activity were measured in the prefrontal cortex, hippocampus, and spinal cord samples. The clinical score increased 14th post-immunization without changes in weight and mobility. Reduced paw strength, mechanical allodynia, and cold allodynia increased in the PMS-EAE animals. PMS-EAE mice showed spontaneous nociception and anxiety-like behavior. AOPPs concentration, NADPH oxidase, and MPO activity increase in CNS structures. Multivariate analyses indicated that the rise of AOPPs levels, NADPH oxidase, and MPO activity influenced the clinical score and cold allodynia. Thus, we indicated the association between non-stimuli painful perception, anxiety-like, and CNS oxidative damage in the PMS-EAE model.
Environmental air pollution is a global health concern, associated with multiple respiratory and systemic diseases. Epidemiological supports continued urbanization and industrialization increasing the prevalence of inhalation exposures. Exposure to these inhaled pollutants induces toxicity via activation of numerous cellular mechanisms including oxidative stress, autophagy, disrupted cellular metabolism, inflammation, tumorigenesis, and others contributing to disease development. The mechanistic target of rapamycin (mTOR) is a key regulator involved in various cellular processes related to the modulation of metabolism and maintenance of homeostasis. Dysregulation of mTOR occurs following inhalation exposures and has also been implicated in many diseases such as cancer, obesity, cardiovascular disease, diabetes, asthma, and neurodegeneration. Moreover, mTOR plays a fundamental role in protein transcription and translation involved in many inflammatory and autoimmune diseases. It is necessary to understand inhalation exposure-induced dysregulation of mTOR since it is key regulator which may contribute to numerous disease processes. This mini review evaluates the available literature regarding several types of inhalation exposure and their impacts on mTOR signaling. Particularly we focus on the mTOR signaling pathway related outcomes of autophagy, lipid metabolism, and inflammation. Furthermore, we will examine the implications of dysregulated mTOR pathway in exposure-induced diseases. Throughout this mini review, current gaps will be identified related to exposure-induced mTOR dysregulation which may enable the targeting of mTOR signaling for the development of therapeutics.
Vaccines and methods for making and using the same. An example vaccine may be a vaccine against enterotoxigenic  Escherichia coli . The vaccine may include an  Escherichia coli  strain. The  Escherichia coli  strain may produce K88 fimbria and a fusion protein including a mutant LT enterotoxin linked with a STb enterotoxin. An example method for producing a vaccine for porcine post-weaning diarrhea may include providing a first strain of  Escherichia coli.  The strain may include the  elt AB gene and the  est B gene. The method may also include amplifying the  elt AB gene, mutating the  elt AB gene, generating a genetic fusion of the mutant  elt AB gene with the  est B gene, and transforming a second strain of  Escherichia 
 coli  with the genetic fusion.
Previous studies have rarely investigated the role of non-vitamin K oral anticoagulants (NOAC) and warfarin in the secondary prevention of ischemic stroke patients with nonvalvular atrial fibrillation (NVAF). In this study, we compared the effectiveness and safety of NOAC and warfarin for secondary prevention in Korean ischemic stroke patients with NVAF. Based on the Korean National Health Insurance Service Database, this study included 21,064 oral anticoagulants-naïve acute ischemic stroke patients with NVAF between July 2015 and June 2019. The main study outcomes included ischemic stroke, systemic embolism, major bleeding, and death. During the observational periods, NOAC users had a significantly decreased risk of ischemic stroke + systemic embolism (adjusted hazard ratio [aHR] 0.86; 95% confidence interval [CI] 0.78-0.95), ischemic stroke (aHR 0.89; 95% CI 0.81-0.99), major bleeding (aHR 0.78; 95% CI 0.68-0.89), and all-cause death (aHR 0.87; 95% CI 0.81-0.93). Standard-dose NOAC users had a lower risk of ischemic stroke, systemic embolism, and major bleeding events than warfarin users. In contrast, low-dose NOAC users did not differ in risk from warfarin users for all outcomes. In conclusion, NOACs were associated with a lower risk of secondary thromboembolic events and bleeding complications in Korean ischemic stroke patients with NVAF than warfarin.
All subjects will start on 1mg glimepiride/10 mg atorvastatin fixed dose combination (FDC) and either treatment can be titrated up based on fasting glucose or LDL levels. The following glimepiride/atorvastations FDCs will be available for use 1mg/10mg, 2mg/10mg, 3mg/10mg, 4mg/10mg, 1mg/20mg, 2mg/20mg, 3mg/20mg, 4mg/20mg.
NEW MATERIAL:The titled compound whose branched part is complex branch of maltooligo sugar of glucose and maltoses, panose, glucosylmaltotriose, etc. USE:A base material for medicine, food, cosmetics, etc. and Bifidobacterium growth factor. PREPARATION:For example, polycosyl-cyclodextrin is mixed with maltooligo sugar such as maltose or sugar mixture containing the above-mentioned sugar and then debranching enzyme (e.g. pullulanase) and water are added thereto and the above-mentioned sugar is reacted with the enzyme at pH5.0 and 55 deg.C for 3 days. After reaction, the reaction mixture is purified using a reverse column chromatography and solvent precipitation, etc., to provide the complex branched cyclodextrin.
During the adult life skeletal muscle mass remains fairly constant until the fourth or fifth decade. Then, the slow process of sarcopenia (the age-related loss of muscle mass) is believed to begin. The maintenance of skeletal muscle mass is regulated by a balance between the opposing processes of muscle protein synthesis and muscle protein breakdown. Food intake, dietary protein in particular, stimulates muscle protein synthesis and allows net muscle protein accretion throughout the day, which allows the normal maintenance of muscle mass in healthy individuals. Many studies have described the postprandial muscle protein synthetic response to protein intake and/or physical activity, and these acute findings have led to recommendations for protein intake for both athletes wishing to gain muscle mass as well as patients and elderly individuals to help them maintaining muscle mass. However, translating the acute findings from a single meal to long-term recommendations is perhaps premature, since scientists know very little with regard to how previous consumed meals affect the anabolic responsiveness to subsequent food intake. A characteristic of the adaptation to habitual high or low protein intake is thought to be associated with a change in the amplitude of diurnal cycle of whole body proteins. If this speculation is accurate, it implies that the muscle protein synthetic responses to feeding (differences between fasting and feeding muscle protein synthesis rates) are adapting to differing habitual protein intake, which may reduce (or enhance) the anabolic responsiveness to protein intake.

To gain a more complete scientific understanding, it is necessary to examine whether an adaptation does in fact occur after habitual high or low amounts of protein intake with regard to the anabolic response to subsequent protein intake. In the present investigation, we wish to investigate the impact of the habitual consumption of either high or low protein diets for 14 days on the anabolic responsiveness to a protein meal in healthy elderly. Previous work has determined that whole body adaptations to protein intake occur after \>10 days. Collectively, our findings will be valuable to maximize the skeletal muscle adaptive response to food intake and, ultimately, to develop nutritional strategies for maintenance or enhancement of skeletal muscle mass in elderly men.
The present invention relates to traditional Chinese medicine for losing weight and reducing fat and a preparation method thereof, which belongs to the technical field of medicine. The present invention provides traditional Chinese medicine for losing weight and reducing fat and a preparation method thereof so as to treat simple obesity, and obesity accompanied with hyperlipemia, hypertension, diabetes, amenorrhea, menoxenia, etc. caused by the deficiency of liver-yin and kidney-yin and the stagnation of phlegm dampness. The traditional Chinese medicine for losing weight and reducing weight is characterized in that medicine ingredients and weight percentage comprise: 10 to 15% of fleece-flower roots, 10 to 15% of scrophularia roots, 10 to 15% of orange peels, 4 to 8% of herba leonuri, 4 to 8% of radix gentianae, 3 to 5% of astragalus roots, 25 to 35% of exocarpium benincasae, 10 to 15% of rhubarb and 4 to 8% of spica prunellae. The traditional Chinese medicine can be prepared into granules or capsules. With the functions of weight losing and fat reduction, the present invention is used for treating simple obesity and obesity accompanied with hyperlipemia, hypertension, diabetes, amenorrhea, menoxenia, etc. caused by the deficiency of liver-yin and kidney-yin and the stagnation of phlegm dampness in clinical application. A total effective rate in clinical treatment is 94%.